Laman UtamaNBIX • NASDAQ
Neurocrine Biosciences, Inc.
$115.06
Selepas Waktu Dagangan:
$115.83
(0.67%)+0.77
Tutup: 27 Sep, 8:00:00 PTG GMT-4 · USD · NASDAQ · Penafian
SahamSekuriti tersenarai ASIbu pejabat di AS
Tutup sebelumnya
$115.93
Julat hari
$114.95 - $116.41
Julat tahun
$103.63 - $157.98
Permodalan pasaran
12.34B USD
Bilangan Purata
1.06J
Nisbah P/E
34.74
Hasil dividen
-
Pertukaran utama
NASDAQ
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD)Jun 2024Perubahan T/T
Hasil
590.20J30.37%
Perbelanjaan pengendalian
242.00J9.11%
Pendapatan bersih
65.00J-31.94%
Margin untung bersih
11.01-47.82%
Pendapatan bagi setiap syer
1.6330.40%
EBITDA
155.20J97.20%
Kadar cukai berkesan
34.08%—
Jumlah aset
Jumlah liabiliti
(USD)Jun 2024Perubahan T/T
Pelaburan tunai dan jangka pendek
1.04B6.37%
Jumlah aset
3.30B26.48%
Jumlah liabiliti
795.80J4.70%
Jumlah ekuiti
2.51B—
Syer tertunggak
100.98J—
Harga kepada buku
4.66—
Pulangan pada aset
10.91%—
Pulangan pada modal
13.21%—
Perubahan bersih dalam tunai
(USD)Jun 2024Perubahan T/T
Pendapatan bersih
65.00J-31.94%
Tunai daripada operasi
64.60J-64.03%
Tunai daripada pelaburan
-28.20J77.60%
Tunai daripada pembiayaan
-293.00J-10,203.45%
Perubahan bersih dalam tunai
-256.60J-553.36%
Aliran tunai bebas
-96.66J-195.52%
Perihal
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Diasaskan
1992
Pekerja
1,500
Cari
Kosongkan carian
Tutup carian
Apl Google
Menu utama